An observational study in Huntington Disease, sponsored by University Hospital, Bordeaux. Completed at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-02-20.
Sponsored by University Hospital, Bordeaux · Observational
The study proposes to identify deviant speech dimensions in patients with HD at presymptomatic and declared stages of the disease, compared to healthy subjects, using the computerized MonPaGe speech protocol. This tool is based on a multidimensional and quantified assessment of voice and speech, by a set of targeted acoustic and perceptual criteria.
Huntington's disease (HD) is a neurodegenerative disorder of the central nervous system, of genetic etiology. It manifests itself in motor, cognitive and psychiatric disorders, which progressively worsen until the patient is grabbed. Motor speech performance disorders are present from the early stage of the disease. These difficulties, which progressively worsen until the end of the patient's life, lead to a communication disorder and constitute a major handicap with social withdrawal, loss of self-esteem and isolation, which are always very painfully experienced by patients and their entourage. Dysarthria in the HD has been very little studied, which makes its speech therapy uncodified. According to the most widely used classification by speech therapists and neurologists, the Darley classification (1975), the speech disorders observed in the HD are included in the heterogeneous group of hyperkinetic dysarthria, whose contours and properties are ill-defined. In this context, a more precise knowledge of speech disorders in the HD appears necessary to identify and characterize the different types of dysarthria and the dysfunctions associated with each level of production (respiration, phonation, resonance, articulation, prosody) and thus improve speech language therapy.
The investigators propose to use an acoustic evaluation to support the perceptual evaluation, available in the MonPaGe protocol, to describe the fine characteristics of the speech disorders in the HD and to define objective markers of dysarthria in this disease for francophone patients.
Each patient is seen in the framework of his annual follow-up consultation in the Competence Center mdH of Bordeaux University Hospital or in the Reference Center mdH of the hospital Henri Mondor of Créteil, for an evaluation of his speech with the computerized tool MonPaGe. A first speech evaluation with the BECD (Auzou, 2006) during 30 minutes is proposed to exclude very severe dysarthria. At the end of this rapid test subtest, the subjects who obtain a perceptive score \<16 are offered the complete assesment of the MonPaGe computerized protocol (30 minutes).The application records directly and anonymously stores speech productions made by the patient.The productions are transmitted to the Phonetics and Phonology Laboratory of Paris (UMR 7018 CNRS / Sorbonne Nouvelle), via a secure large data exchange server and are subject to a perceptual and acoustic evaluation a posteriori.
293 studies on the registry are indexed under Huntington Disease; 54 are open to participants now.
This study's enrollment of 150 is above the median of 90 across 82 observational studies indexed under Huntington Disease.
Browse Huntington Disease studies →University Hospital, Bordeaux is the lead sponsor of 806 studies on the registry; 197 are open to participants now.
Counted across the registry records on this site, refreshed daily.
patients with Huntington's disease at presymptomatic and declared stages of the disease.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Each patient is seen in the framework of his annual follow-up consultation, for an evaluation of his speech with the computerized tool MonPaGe.
Other: Speech evaluation with the clinical evaluation of dysarthria · Other: complete assessment of the MonPaGe computerized protocol
A first speech evaluation with the clinical evaluation of dysarthria during 30 minutes is proposed to exclude very severe dysarthria.
The application records directly and anonymously stores speech productions made by the patient.
Determination of the intelligibility score.
Defined as the number of words correctly recognized by the evaluator (score out of 15).
Time frame: Day 1
Determination of the maximum phonation time.
Expressed in milliseconds.
Time frame: Day 1
Determination of the phonation characteristics.
Described as the mean and standard deviation of fundamental frequency (in Hz),
Time frame: Day 1
Determination of the intensity modulation capacities.
Based on a scale of 0 to 4.
Time frame: Day 1
Determination of the Coarticulation.
Expressed in Hz. Extracted from the spectral properties of the acoustic signal of certain words.
Time frame: Day 1
Determination of the prosody.
assessed on a scale 0 to 4 on particular sentences.
Time frame: Day 1
Determination of the diadocokinesies,
assessed on two scales: precision (0 to 4) and control (0 to 4).
Time frame: Day 1
Determination of the articulation rate.
expressed in syllabs per second.
Time frame: Day 1
Determination of the Huntington's disease stage.
The Huntington's disease stage will be determined based on the Total Functional Capacity (TFC) and the Total Motor Score (TMS) scales of the Unified Huntington's Disease Rating Scale: * pre-symptomatic stage: TFC = 13 / TMS \<5 * light stage: TFC ≥11 / TMS 5 to 20 * moderate stage: TFC = 7 to 10 / TMS: 20 to 40
Time frame: Day 1
Determination of the clinical motor forms of the Huntington's disease.
The clinical motor forms of Huntington disease will be determined by the motor UHDRS scale (Total Motor Score), which evaluates oculomotricity, skill and manual planning, bradykinesia, dystonia and rigidity, chorea and walking, balance, lingual protrusion and dysarthria.
Time frame: Day 1
Determination of the level of cognitive impairment
The level of cognitive impairment will be assessed by the cognitive score as per the Unified Huntington's Disease Rating Scale.
Time frame: Day 1
This study is completed, as verified in Feb 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Bordeaux →